ECSP088528A - Formulación de profármacos para el vhc - Google Patents

Formulación de profármacos para el vhc

Info

Publication number
ECSP088528A
ECSP088528A EC2008008528A ECSP088528A ECSP088528A EC SP088528 A ECSP088528 A EC SP088528A EC 2008008528 A EC2008008528 A EC 2008008528A EC SP088528 A ECSP088528 A EC SP088528A EC SP088528 A ECSP088528 A EC SP088528A
Authority
EC
Ecuador
Prior art keywords
hcv
drugs
formulation
butyryloxy
isobutyrate
Prior art date
Application number
EC2008008528A
Other languages
English (en)
Inventor
Wantanee Phuapradit
Navnit Hargovindas Shah
Hashim A Ahmed
Thomas Vernon Alfredson
Kondamraj Birudaraj
Michael Thomas Brandl
Dimitrios Stefanidis
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of ECSP088528A publication Critical patent/ECSP088528A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención está relacionada con una composición farmacéutica que contiene una suspensión sólida preparada mediante extrusión por fusión en calor de isobutirato de (2R,3S,4R,5R)-5-(4-amino-2-oxo-2H-pirimidin-1-il)-2-azido-3,4-bis-iso-butiriloxi-tetrahidro-furan-2-ilmetilo; clorhidrato (I) y un copolímero de bloques de polietilenglicol (PEG)/polipropilenglicol (PPG).
EC2008008528A 2005-12-14 2008-06-12 Formulación de profármacos para el vhc ECSP088528A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75014605P 2005-12-14 2005-12-14
US83059406P 2006-07-12 2006-07-12

Publications (1)

Publication Number Publication Date
ECSP088528A true ECSP088528A (es) 2008-07-30

Family

ID=37806115

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2008008528A ECSP088528A (es) 2005-12-14 2008-06-12 Formulación de profármacos para el vhc

Country Status (21)

Country Link
US (1) US7795237B2 (es)
EP (1) EP1962808B1 (es)
JP (1) JP5649783B2 (es)
KR (1) KR20080089344A (es)
AR (1) AR058313A1 (es)
AT (1) ATE482690T1 (es)
AU (1) AU2006326130B2 (es)
BR (1) BRPI0619890A2 (es)
CA (1) CA2631498A1 (es)
CR (1) CR10026A (es)
DE (1) DE602006017257D1 (es)
DK (1) DK1962808T3 (es)
EC (1) ECSP088528A (es)
IL (1) IL191791A (es)
MA (1) MA30056B1 (es)
NO (1) NO20082563L (es)
PL (1) PL1962808T3 (es)
PT (1) PT1962808E (es)
RU (1) RU2435592C2 (es)
TW (1) TWI382840B (es)
WO (1) WO2007068615A2 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005072710A2 (en) * 2004-01-28 2005-08-11 Johns Hopkins University Drugs and gene carrier particles that rapidly move through mucous barriers
US20100038816A1 (en) * 2006-08-16 2010-02-18 Novartis Ag Method of making solid dispersions of highly crystalline therapeutic compounds
DE602007012559D1 (de) * 2006-09-08 2011-03-31 Univ Johns Hopkins H die schleimhaut
CA2682638C (en) 2007-03-29 2012-07-17 F. Hoffmann-La Roche Ag Pharmaceutical composition comprising (2r, 3s, 4r, 5r)-5-(4-amino-2-oxo-2h-pyrimidin-1-yl)-2-azido-3,4-bis-iso-butyryloxy-tetrahydro-furan-2-ylmethyl isobutyrate
ES2513415T3 (es) * 2009-01-21 2014-10-27 F. Hoffmann-La Roche Ag Composiciones farmacéuticas que comprenden un profármaco inhibidor de la polimerasa del VHC
AR075180A1 (es) * 2009-01-29 2011-03-16 Novartis Ag Formulaciones orales solidas de una pirido-pirimidinona
GB0909680D0 (en) 2009-06-05 2009-07-22 Euro Celtique Sa Dosage form
MX337050B (es) * 2010-01-28 2016-02-10 Riboscience Llc Compuestos 4'-azido-nucleósidos como anti-vhc.
CA2798885C (en) 2010-05-10 2014-11-18 Euro-Celtique S.A. Combination of active loaded granules with additional actives
BR112012028773A2 (pt) 2010-05-10 2016-07-19 Euro Celtique Sa composições farmacêuticas compreendendo hidromorfona e naloxona
AU2011252040C1 (en) 2010-05-10 2015-04-02 Euro-Celtique S.A. Manufacturing of active-free granules and tablets comprising the same
WO2012061703A1 (en) * 2010-11-05 2012-05-10 The Johns Hopkins University Compositions and methods relating to reduced mucoadhesion
WO2012062691A1 (en) * 2010-11-09 2012-05-18 F. Hoffmann-La Roche Ag Pharmaceutical compositions for treating hcv infections
EP2455068A1 (en) * 2010-11-09 2012-05-23 F. Hoffmann-La Roche AG Pharmaceutical composition for treating HCV infections
JP5917964B2 (ja) * 2012-03-19 2016-05-18 富士ゼロックス株式会社 錠剤、錠剤の製造方法、錠剤管理装置、錠剤照合装置及びプログラム
US9827191B2 (en) 2012-05-03 2017-11-28 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
KR102140989B1 (ko) * 2012-05-03 2020-08-04 칼라 파마슈티컬스, 인크. 개선된 점막 수송을 나타내는 제약 나노입자
US11596599B2 (en) 2012-05-03 2023-03-07 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
ES3055223T3 (en) 2012-05-03 2026-02-10 Alcon Inc Pharmaceutical nanoparticles showing improved mucosal transport
HK1217092A1 (zh) 2013-02-15 2016-12-23 Kala Pharmaceuticals, Inc. 治疗性化合物及其用途
BR112015020139A2 (pt) 2013-02-20 2017-07-18 Kala Pharmaceuticals Inc compostos terapêuticos e usos dos mesmos
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
KR20160099084A (ko) 2013-11-01 2016-08-19 칼라 파마슈티컬스, 인크. 치료 화합물의 결정질 형태 및 그의 용도
EP3068397A1 (en) 2013-11-13 2016-09-21 Euro-Celtique S.A. Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome
CA3036336A1 (en) 2016-09-08 2018-03-15 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
CA3036065A1 (en) 2016-09-08 2018-03-15 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
EP3509423A4 (en) 2016-09-08 2020-05-13 Kala Pharmaceuticals, Inc. CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF
EP3381479A1 (de) * 2017-03-29 2018-10-03 ARTOSS GmbH Trägerzusammensetzung für knochenersatzmaterialien

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2260319B (en) * 1991-10-07 1995-12-06 Norsk Hydro As Acyl derivatives of nucleosides and nucleoside analogues having anti-viral activity
EP2272536B1 (en) * 1996-06-26 2016-05-04 Board of Regents, The University of Texas System Hot-melt extrudable Pharmaceutical formulation
AU754370B2 (en) * 1997-06-03 2002-11-14 Itochu Techo-Chemical Inc. Natural antitumor or antiviral substances and use of the same
ATE232087T1 (de) * 1997-10-27 2003-02-15 Merck Patent Gmbh Feste lösungen und dispersionen von eines schlecht wasserlöslichen wirkstoffes
RU2187509C1 (ru) * 2001-03-26 2002-08-20 Закрытое акционерное общество "Производственно-коммерческая Ассоциация АЗТ" Производные 5'-h-фосфоната 3'-азидо-3'-дезокситимидина и фармацевтические композиции на их основе
BR0209325A (pt) * 2001-05-03 2004-07-20 Hoffmann La Roche Forma de dosagem farmacêutica de mesilato de nelfinavir amorfo
DE10162593A1 (de) * 2001-12-19 2003-07-03 Menarini Ricerche Spa Stabilisierte topische Brivudin-Formulierungen
DE10208344A1 (de) * 2002-02-27 2003-09-04 Roehm Gmbh Schmelzextrusion von Wirkstoffsalzen
TWI332507B (en) * 2002-11-19 2010-11-01 Hoffmann La Roche Antiviral nucleoside derivatives
US20050044529A1 (en) * 2003-08-20 2005-02-24 Microsoft Corporation Task library of task data for a plurality of components on a computer system
US20050048112A1 (en) * 2003-08-28 2005-03-03 Jorg Breitenbach Solid pharmaceutical dosage form

Also Published As

Publication number Publication date
US7795237B2 (en) 2010-09-14
ATE482690T1 (de) 2010-10-15
WO2007068615A3 (en) 2007-09-07
DK1962808T3 (da) 2010-11-08
KR20080089344A (ko) 2008-10-06
PT1962808E (pt) 2010-10-29
CA2631498A1 (en) 2007-06-21
NO20082563L (no) 2008-07-03
WO2007068615A2 (en) 2007-06-21
DE602006017257D1 (de) 2010-11-11
BRPI0619890A2 (pt) 2011-10-25
PL1962808T3 (pl) 2011-03-31
TW200803873A (en) 2008-01-16
CR10026A (es) 2008-07-29
MA30056B1 (fr) 2008-12-01
JP2009519289A (ja) 2009-05-14
US20070202175A1 (en) 2007-08-30
EP1962808A2 (en) 2008-09-03
AR058313A1 (es) 2008-01-30
JP5649783B2 (ja) 2015-01-07
TWI382840B (zh) 2013-01-21
AU2006326130A1 (en) 2007-06-21
IL191791A (en) 2011-06-30
RU2435592C2 (ru) 2011-12-10
AU2006326130B2 (en) 2011-09-22
IL191791A0 (en) 2008-12-29
EP1962808B1 (en) 2010-09-29
RU2008128361A (ru) 2010-01-20

Similar Documents

Publication Publication Date Title
ECSP088528A (es) Formulación de profármacos para el vhc
EA201270738A1 (ru) Модуляторы фармакокинетических свойств лекарственных средств
PY0401585A (es) Formulaciones farmaceuticas liquidas de palonosetron
EP2269631A3 (en) Pharmaceutical compositions comprising botulinum neurotoxin for use in medicine and cosmetics
EA200801926A1 (ru) Таблетки парацетамола с быстрым высвобождением
ECSP088239A (es) Composición de liberación de fármaco sostenida
PL2054411T3 (pl) Nowe związki, ich izomery lub ich farmaceutycznie dopuszczalne sole jako antagoniści receptora waniloidowego oraz zawierające je kompozycje farmaceutyczne
EA200701065A1 (ru) Инъецируемые составы, содержащие нанодисперсный оланзапин
BR0206627A (pt) Formulação farmacêutica
CL2013002241A1 (es) Compuestos derivados de (4,4´-bifeniilbis(1h-imidazol-4,2-diil)-2,1-pirrolidindiil((1s)-1-((2r,6r)-2,4-dimetilltetrahidro-2h-piran-4-il)-2-oxo-2,1-etandiil)))biscarbamato de dimetilo, inhibidores del vhc; compuestos intermediarios; composicion farmaceutica; combinacion farmaceutica; y uso para tratar una infeccion por vhc.
AR054114A1 (es) Composiciones farmaceuticas que comprenden imatinib y un retardador de la liberacion
CL2004000930A1 (es) Compuesto derivado de dihidroquinazolina de formula definida, util para el tratamiento y/o profilaxis de infecciones virales; composicion farmaceutica que comprende al compuesto y uso del compuesto en la preparacion de medicamentos.
ECSP10010167A (es) Composiciones oftálmicas novedosas
BRPI0511966A (pt) composições farmacêuticas contendo polietileno glicol tendo um peso molecular menor do que 600 daltons
WO2005072343A3 (en) Aqueous pharmaceutical compositions 2,6-diisopropylphenol (propofol) and their use
EA200901393A1 (ru) Фармацевтическая композиция, содержащая гестагены и/или эстрогены и 5 метил-(6s)-тетрагидрофолат
GEP20135859B (en) Stable combined pharmaceutical composition
PE20081308A1 (es) Derivados ciclicos como moduladores de la actividad del receptor de quimiocina
AR027360A1 (es) Composicion farmaceutica
WO2008101173A3 (en) Biodegradable compositions and materials
PE20091879A1 (es) Compuestos para el tratamiento de la hepatitis c
AR088838A1 (es) Derivados de imidazol como inhibidores del virus de la hepatitis c
PE20090066A1 (es) Composiciones farmaceuticas en base a granulos de un derivado de azidocitidina y un copolimero de bloques y procedimiento de preparacion
ATE479427T1 (de) Pharmazeutische zusammensetzung mit candesartan- cilexetil
ATE534375T1 (de) Pharmazeutische zusammensetzung mit n-ä2- (diethylamino)ethylü-5-ä(5-fluoro-1,2- dihydro-2- oxo-3h-indol-3-yliden)methylü-2,4-dimethyl-1h- pyrrol-3-carbonsäureamid